All-oral Revumenib, Decitabine, and Venetoclax combo achieves high response rates and durable remissions in tough-to-treat AML patients.
by Issa GC, Cuglievan B (...) Kantarjian HM et 29 al. in J Clin Oncol #MedSky
š get more here
š read the article: https://ascopubs.org/doi/10.1200/JCO-26-01159